← All trials
NCT02188160
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2014
- Primary completion
- Jan 1, 2015
- Completion date
- Mar 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Kala Pharmaceuticals, Inc.Lead sponsor
- Price Vision GroupOverall official - principal investigator
- Total Eye Care, PAOverall official - principal investigator
- Martel Eye Medical GroupOverall official - principal investigator
- Eye Center of Southern CT, P.C.Overall official - principal investigator
- Sall Research Medical CenterOverall official - principal investigator
- Whitsett Vision GroupOverall official - principal investigator
- South Shore Eye CareOverall official - principal investigator
- Ecomprehensive Eye Care, LtdOverall official - principal investigator
- Abrams Eye Center, Cleveland, OHOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.